Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy最新文献

{"title":"Abdominal Massage Decreases Food Intake and Body Weight in High-Fat Diet-Induced Obese Rats Through Upregulating GPR41/GPR43-PYY/GLP-1 Axis.","authors":"Fei Ma, Huanan Li, Caiyin Huang, Chenghao Shuai, Chengfei An, Wei Zhang","doi":"10.2147/DMSO.S492185","DOIUrl":"10.2147/DMSO.S492185","url":null,"abstract":"<p><strong>Background: </strong>Abdominal massage has been found to exert an important role in helping people in overcoming obesity. However, the mechanism by which abdominal massage induces weight loss remains largely unclear.</p><p><strong>Methods: </strong>Healthy male Sprague-Dawley (SD) rats were randomly grouped into standard diet control (15% fat content) group and high-fat diet (HFD, 40% fat content) group. After 6 weeks of high-fat feeding, rats in the HFD group were successfully modeled, and then separated into the HFD group and HFD plus abdominal massage group. Rats in the HFD plus abdominal massage group were then subjected to abdominal massage for 12 continuous days.</p><p><strong>Results: </strong>Compared to the HFD group, abdominal massage could decrease body weight, food intake and abdominal fat index (AFI) of HFD-fed rats. Meanwhile, compared to the HFD group, abdominal massage obviously attenuated mucosal epithelial damage and reduced inflammatory cell infiltration in colon mucosal tissues of HFD-fed rats. Furthermore, compared to the HFD group, abdominal massage significantly increased GPR42 and GPR43 levels in the colon tissues of HFD-fed rats, and upregulated the production of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in colon mucosal tissues of HFD-fed rats.</p><p><strong>Conclusion: </strong>Collectively, abdominal massage could decrease food intake and body weight in HFD-induced obese rats through upregulating GPR41/GPR43-PYY/GLP-1 axis.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1673-1682"},"PeriodicalIF":2.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BOLD MRI to Evaluate the Effects of Sacubitril/Valsartan on Renal Protection in Type 2 Diabetics.","authors":"Limin Zhai, Yue Wang, Li Xiang, Liang-Ping Ni, Deyuan Zhang, Tianrong Pan","doi":"10.2147/DMSO.S507699","DOIUrl":"10.2147/DMSO.S507699","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of sacubitril/valsartan on diabetic nephropathy patients by blood-oxygenation-level dependent-magnetic resonance imaging (BOLD-MRI).</p><p><strong>Methods: </strong>Forty-eight Patients with diabetic kidney disease (DKD) admitted to our hospital from April 2023 to December 2024 were selected. They were divided into two groups based on the treatment obtained. The dapagliflozin group included dapagliflozin 10 mg once daily, and the Sacubitril/valsartan group included a combination of dapagliflozin and sacubitril/valsartan for 12 weeks. The plasma and urine biochemistry parameters of all patients were compared. Meanwhile, renal was scanned by BOLD MRI before and after experiment endpoint.</p><p><strong>Results: </strong>After 12 weeks treatment, biochemical indexes from baseline were improved in both dapagliflozin group and sacubitril/valsartan group. Sacubitril/valsartan treatment significantly reduced UACR and UNAG excretion, as well as decreased the R2* values of the kidney medulla, compared to the dapagliflozin group (p < 0.05).</p><p><strong>Conclusion: </strong>Sacubitril/valsartan can provide protection in DKD by reducing UACR and UNAG excretion while improving the oxygenation of the medulla area of the kidney, beyond its hypoglycemic and antihypertensive effects.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1661-1670"},"PeriodicalIF":2.8,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Type 2 Diabetes Mellitus Patients: A Retrospective Cytopeutics' Registry Study.","authors":"Sze-Piaw Chin, Li Ting Kee, Muzaida Aminah Mohd, Kong Yong Then","doi":"10.2147/DMSO.S507801","DOIUrl":"10.2147/DMSO.S507801","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, leading to elevated blood glucose levels. Cellular therapies offer promise for improving hyperglycemia in T2DM. This retrospective study aimed to assess the clinical effectiveness of intravenous allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusion in T2DM patients through various clinical evaluations, focusing on systemic inflammation, metabolic dysfunction, and insulin resistance.</p><p><strong>Methods: </strong>The data from a total of 218 T2DM patients who attended for follow-up after 6 months, and 83 patients after 12 months after receiving 50-100×10⁶ allogeneic UC-MSCs were analyzed. Blood and urine samples were collected at baseline and follow-up. Key evaluations included changes in anthropometry, diabetes indices, lipids, liver, renal, hormonal, and inflammatory markers.</p><p><strong>Results: </strong>All patients demonstrated satisfactory outcomes, without adverse effects. Significant reductions in HbA1c levels were observed at 6-months (p<0.001) and 12-months (p=0.016). Insulin (p=0.048) and HOMA-IR (p=0.007) levels significantly reduced within 6-months, with same trend at 12-months. ALT and GGT levels significantly decreased (p<0.05), indicating a reduction in liver inflammation. hs-CRP level among patients with higher inflammation were also reduced at 6-months (p=0.073) and significantly at 12-months (p=0.016). Testosterone (p=0.050) and estradiol (p=0.043) levels increased in males and females, respectively, during 12-month follow-up. Additionally, estimated glomerular filtration rate (eGFR) and creatinine levels improved in stage 2 chronic kidney disease (CKD) at 6- and 12-month (p<0.05), indicating recovered renal function for those in early stage of CKD.</p><p><strong>Conclusion: </strong>Allogeneic UC-MSCs infusion is safe for patients with T2DM and is associated with overall health outcomes, with sustained benefits up to 12 months. Notably, the treatment significantly improved metabolic indices including glycemic control, liver and renal profile and systemic subclinical inflammation. These findings provide a basis for further exploration of UC-MSCs in managing T2DM in proper randomized control trial, by addressing both metabolic dysregulation and inflammation.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1643-1659"},"PeriodicalIF":2.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) as a Risk Factor for Recurrent Ischemic Stroke in Type 2 Diabetes.","authors":"Ruomeng Chen, Kun Zhang, Hui Liu, Lijuan Liu, Hui Li, Yan Yan, Zhou Zhou, Chaoyue Meng, Xuelin Wang, Haoran Wu, Ruihan Miao, Rui Wang, Xiaoyun Liu","doi":"10.2147/DMSO.S502459","DOIUrl":"10.2147/DMSO.S502459","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effect of LP(a) on recurrent ischemic stroke among persons with and without diabetes, providing a basis for the precise management of patients with recurrent ischemic stroke with diabetes in clinical practice.</p><p><strong>Methods: </strong>This study was conducted on consecutive patients with cerebral infarction diagnosed between January 2019 and March 2023 in the Second Hospital of Hebei Medical University. Stratified analyses were performed according to LP(a) level (≤/>90th percentile) and logistic regression modeling was performed to investigate the relationship between LP(a) and recurrent ischemic stroke with or without T2DM.</p><p><strong>Results: </strong>In the final enrollment of 2029 patients, the number of recurrent ischemic stroke according to LP(a) >90th percentile combined with T2DM was 59.15%, which was significantly higher than in LP(a) ≤90th percentile combined with T2DM (46.17%, <i>P</i>=0.039). After multivariate adjustment, LP(a) >90th percentile emerged as an independent risk factor for patients with T2DM (OR=2.062, 95% CI 1.218-3.489, <i>P</i>=0.007). In patients with large artery atherosclerotic ischemic stroke, LP(a) was an independent risk factor for recurrent ischemic stroke in diabetic patients (OR=2.553, 95%CI 1.385-4.707, <i>P</i> = 0.003), while this was not in non-diabetic patients (<i>P</i> = 0.228).</p><p><strong>Conclusion: </strong>LP(a) is an independent risk factor for recurrent ischemic stroke in the diabetic population but not in nondiabetic individuals. Simple categorization based on the presence or absence of comorbid T2DM significantly influences the association between LP(a) and recurrent ischemic stroke. Therefore, in clinical practice, for ischemic stroke patients with comorbid diabetes, the LP(a) level should be more strictly controlled.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1631-1641"},"PeriodicalIF":2.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Integrated Analysis of Single-Cell RNA-Seq and Bulk RNA-Seq Combined with Multiple Machine Learning Identified a Novel Immune Signature in Diabetic Nephropathy [Corrigendum].","authors":"","doi":"10.2147/DMSO.S540734","DOIUrl":"https://doi.org/10.2147/DMSO.S540734","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.2147/DMSO.S413569.].</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1629-1630"},"PeriodicalIF":2.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Therapeutic Effect and Mechanism of Traditional Chinese Medicine in Type 2 Diabetes Mellitus and Its Complications.","authors":"Song Wen, Haina Zhang, Xing Huang, Congcong Wang, Meiyuan Dong, Chaoxun Wang, Chenglin Xu, Yue Yuan, Yanyan Li, Ligang Zhou, Xinlu Yuan","doi":"10.2147/DMSO.S517874","DOIUrl":"10.2147/DMSO.S517874","url":null,"abstract":"<p><p>Traditional Chinese Medicine (TCM) has recently emerged as a beacon for the treatment of diabetes and its complications. Many TCMs that are commonly used, have the potentially demonstrated significant anti-diabetic effects. The mechanisms of these effects have been extensively discussed using modern techniques, such as genomics, mass spectrometry, and network pharmacology. Studies have demonstrated that TCM can influence glucose metabolism and pancreatic function via a diverse array of mechanisms including PI3K/AKT and AMPK pathways. TCM not only exhibits potential in the treatment of diabetes but also reduces the risk of diabetic complications. It is effective in the treatment of diabetic nephropathy (DN), diabetic retinopathy (DR), diabetic neuropathy (DPN), diabetic cardiomyopathy, and peripheral angiopathy. Research has demonstrated that prescriptions, Chinese herbal medicines, and their extracts play a role in a variety of molecular mechanisms such as antioxidation, apoptosis regulation, hypoxia improvement, autophagy, and promotion of glucose and lipid metabolism. The antioxidant properties of TCM have received considerable attention. Recent studies have demonstrated that they are capable of effectively eliminating free radicals from the body and reducing damage to cells caused by oxidative stress. Consequently, they are crucial in the treatment of diabetes and its associated complications. This review summarizes the ever-expanding scope of TCM applicability in the field of diabetes, providing crucial support and innovative ideas for modern healthcare. TCMs could help seek more effective pharmacological targets in basic study and as well serve as the complement to the strategy of diabetic prevention and treatment benefiting the patients. More and more large series of RCT and clinical investigations will eventually examine the efficacy of specific TCM formulas on the therapeutic effect of DM and its complication where currently treatments could not be satisfied.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1599-1627"},"PeriodicalIF":2.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationships Between Lifestyle Behaviors, Health Perceptions, and Psychosocial Outcomes of Metabolic Syndrome Severity.","authors":"Bryce T Daniels, Sumihiro Suzuki, Kelly Karavolos, Betty M Drees, Barbara Lohse, Lisa Bailey-Davis, Jacinda M Nicklas, Kevin S Masters, Lynda H Powell","doi":"10.2147/DMSO.S484850","DOIUrl":"10.2147/DMSO.S484850","url":null,"abstract":"<p><strong>Purpose: </strong>The prevalence of metabolic syndrome (MetS) continues to increase. The severity of MetS can be defined by the number of components or, more recently, a continuous MetS severity score (MetSSS). However, studies that examine lifestyle factors predictive of MetS severity, in general, are lacking. This study aims to compare lifestyle behaviors (eg, physical activity and diet), health perceptions (eg, overall and mental health perceptions), and psychosocial outcomes (eg, perceived stress and social support) among people with a varied number of MetS components and to evaluate associations with MetSSS.</p><p><strong>Patients and methods: </strong>This cross-sectional study utilized baseline data from a randomized controlled trial of 618 participants with MetS recruited from 5 different sites across the US We collected data using accelerometers, standard questionnaires, bloodwork, and doing physical measurements. We used a series of separate linear regression models (unadjusted and adjusted) to evaluate differences in lifestyle behaviors, health perceptions, and psychosocial factors between people with 3, 4, and 5 MetS components. We conducted additional linear regression models (unadjusted and adjusted) to assess the association between these same variables and a continuous MetSSS.</p><p><strong>Results: </strong>Lifestyle behaviors, health perceptions, and psychosocial factors were not different among people with 3, 4, and 5 MetS components. However, in the adjusted models, a lower MetSSS was associated with more average daily steps (β = -631.69, <i>p</i> < 0.001), healthier overall health perception (β = -0.14, <i>p</i> = 0.014), more social support for physical activity from friends (β = -0.89, <i>p</i> = 0.011) and more social support for healthy eating from friends (β = -0.42, <i>p</i> = 0.015).</p><p><strong>Conclusion: </strong>The MetSSS was shown to be more sensitive to modifiable lifestyle factors compared to the number of MetS components, indicating the importance of using the MetSSS in lifestyle interventions targeting MetS to achieve MetS remission.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1575-1585"},"PeriodicalIF":2.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Body Composition and Hypertension in Postmenopausal Women with Osteoporosis-A Single-Center Cross-Sectional Study.","authors":"Shu Jiang, Yu Fu, Lu Chen, Yi Qiu","doi":"10.2147/DMSO.S515563","DOIUrl":"10.2147/DMSO.S515563","url":null,"abstract":"<p><strong>Objective: </strong>To research the association among body composition and the presence or absence of comorbid hypertension in postmenopausal women with osteoporosis.</p><p><strong>Methods: </strong>Postmenopausal osteoporosis sufferers according to whether they are combined with hypertension or not were divided into two groups: hypertension-negative group and hypertension-positive group. Compare the indicators of the two groups, find out the independent influencing factors, and test the test effect of influencing factors. Establish a prediction model and analyse the relationship between the prediction model and blood pressure.</p><p><strong>Results: </strong>There were statistical differences in age, 25-hydroxyvitamin D, uric acid, homocysteine, history of diabetes, high-density lipoprotein cholesterol, body mass index (BMI), waist circumference (WC), body fat mass (BFM), body fat percentage (PBF) and visceral fat area (VFA) between two groups. Logistic analysis showed that BFM and VFA were independent influencing factors for hypertension, with for BFM (OR, 0.46; 95% CI, 0.24-0.90; <i>p</i>=0.024) and VFA (OR, 1.06; 95% CI, 1.01-1.13; <i>p</i>=0.031). Based on the body composition parameters of BMI, WC, BFM, PBF and VFA, the area under the curve of the prediction model for detecting hypertension was 0.694 by receiver-operating characteristic test (p < 0.001). Using generalized additive model, the predictor were found to have a significant dose-response relationship with systolic blood pressure (SBP), but not with diastolic blood pressure.</p><p><strong>Conclusion: </strong>BFM and VFA are independent influencing factors for hypertension in postmenopausal osteoporosis patients. In postmenopausal osteoporosis patients, the predictive model composed of body composition related parameters has certain significance in predicting whether postmenopausal osteoporosis is complicated with hypertension. The effect of the prediction model on blood pressure was mainly reflected in SBP.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1587-1598"},"PeriodicalIF":2.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tryptophan Indole Derivatives: Key Players in Type 2 Diabetes Mellitus.","authors":"Yingli Wu, Tiangang Li, Biaohua Chen, Yi Sun, Liyun Song, Yinying Wang, Yao Bian, Yong Qiu, Zhongshan Yang","doi":"10.2147/DMSO.S511068","DOIUrl":"10.2147/DMSO.S511068","url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is a complex clinical syndrome characterized by insulin resistance and associated with abnormal amino acid metabolism. Tryptophan is an aromatic dietary amino acid that affects T2DM by regulating glycolipid metabolism and insulin resistance. When tryptophan reaches the intestine, it is converted by gut microbiota and tryptophanase into indole derivatives such as indoleacetic acid, indolepropionic acid, and indolealdehyde. These indole derivatives may enhance insulin sensitivity, stimulate insulin secretion, and exert functions such as lowering blood glucose, regulating hepatic oxidative stress, reducing intestinal inflammation, and improving islet cell morphology by acting on the aryl hydrocarbon receptor (AHR) or Pregnane X receptor (PXR). In summary, this review aims to examine the interactions between tryptophan indole derivatives and T2DM thoroughly, elucidate potential therapeutic approaches, and pinpoint areas for further research.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1563-1574"},"PeriodicalIF":2.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-35 Ameliorates Myocardial Strain in Mice with T2DM-Induced Cardiac Injury: Assessment by Layer-Specific Strain.","authors":"Ziying Wang, Leilei Han, Mingyi Dong, Yunman Liu, Xiangsui Hu, Long Huang, Chunquan Zhang, Liangyun Guo, Shengbo Liu, Lingmin Liao","doi":"10.2147/DMSO.S510594","DOIUrl":"https://doi.org/10.2147/DMSO.S510594","url":null,"abstract":"<p><strong>Purpose: </strong>The established association between endothelial dysfunction and the pathogenesis of cardiovascular disease in diabetic individuals has been well-documented. Interleukin-35 (IL-35) can suppress inflammatory processes and ameliorate endothelial dysfunction. This study aimed to evaluate the effect of IL-35 treatment on diabetic mice with diabetes-induced cardiac injury using layer-specific strain analysis.</p><p><strong>Patients and methods: </strong>Twenty-six mice were allocated into three groups: the control group (CON, n=10), the diabetic group (DM, n=10), and the diabetic group treated with IL-35 (DMIL, n=6). The DM and DMIL groups were subjected to a high-fat diet and streptozotocin to induce diabetes, with the DMIL group receiving an additional 6 weeks of IL-35 treatment. Measurements of body weight, blood glucose levels, routine echocardiographic parameters, and layer-specific strain were conducted at baseline, post-diabetes induction, and post-treatment. Morphological changes in cardiomyocytes were examined in pathological heart sections, and cardiac inflammation was detected by protein immunoblotting.</p><p><strong>Results: </strong>After inducing diabetes, diabetic mice exhibited notable systolic and diastolic dysfunction. IL-35 treatment significantly reduced myocardial inflammatory infiltration and improved myocardial fibrosis in the DMIL group in comparison to the DM group. Only diastolic function E/e' showed a significant improvement when comparing conventional echocardiograms between the DMIL and DM groups. In the context of layered strain analysis, the DMIL group exhibited a notable enhancement in middle and epicardial global longitudinal strain and global radial strain when compared to the DM group.</p><p><strong>Conclusion: </strong>IL-35 can enhance myocardial function in diabetic mice. Layer-specific strain could serve as a valuable tool for evaluating interventions in diabetes.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1551-1562"},"PeriodicalIF":2.8,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}